JP2014523851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523851A5
JP2014523851A5 JP2013546480A JP2013546480A JP2014523851A5 JP 2014523851 A5 JP2014523851 A5 JP 2014523851A5 JP 2013546480 A JP2013546480 A JP 2013546480A JP 2013546480 A JP2013546480 A JP 2013546480A JP 2014523851 A5 JP2014523851 A5 JP 2014523851A5
Authority
JP
Japan
Prior art keywords
group
substituted
optionally substituted
ring
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546480A
Other languages
English (en)
Japanese (ja)
Other versions
JP5976011B2 (ja
JP2014523851A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013546480A priority Critical patent/JP5976011B2/ja
Priority claimed from JP2013546480A external-priority patent/JP5976011B2/ja
Publication of JP2014523851A publication Critical patent/JP2014523851A/ja
Publication of JP2014523851A5 publication Critical patent/JP2014523851A5/ja
Application granted granted Critical
Publication of JP5976011B2 publication Critical patent/JP5976011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546480A 2011-04-05 2012-04-05 スルホンアミド誘導体およびその用途 Active JP5976011B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013546480A JP5976011B2 (ja) 2011-04-05 2012-04-05 スルホンアミド誘導体およびその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011084100 2011-04-05
JP2011084100 2011-04-05
JP2013546480A JP5976011B2 (ja) 2011-04-05 2012-04-05 スルホンアミド誘導体およびその用途
PCT/JP2012/059949 WO2012137982A2 (en) 2011-04-05 2012-04-05 Sulfonamide derivative and use thereof

Publications (3)

Publication Number Publication Date
JP2014523851A JP2014523851A (ja) 2014-09-18
JP2014523851A5 true JP2014523851A5 (enExample) 2015-05-21
JP5976011B2 JP5976011B2 (ja) 2016-08-23

Family

ID=46028103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546480A Active JP5976011B2 (ja) 2011-04-05 2012-04-05 スルホンアミド誘導体およびその用途

Country Status (4)

Country Link
US (1) US9527807B2 (enExample)
EP (1) EP2694472B1 (enExample)
JP (1) JP5976011B2 (enExample)
WO (1) WO2012137982A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134654B2 (ja) 2012-02-08 2017-05-24 武田薬品工業株式会社 複素環化合物およびその用途
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
ES2663614T3 (es) 2014-03-24 2018-04-16 Bayer Cropscience Aktiengesellschaft Procedimiento de preparación de derivados de 3,5-bis(haloalquil)pirazol a partir de alfa, alfa-dihaloaminas y cetiminas
EP3015458A1 (en) * 2014-11-03 2016-05-04 Bayer CropScience AG Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines
HRP20220127T1 (hr) 2016-02-04 2022-04-15 Takeda Pharmaceutical Company Limited Supstituirani spoj piperidina i njegova uporaba
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
MY202221A (en) * 2017-08-03 2024-04-17 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
EP3663281B1 (en) * 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US11407748B2 (en) 2017-10-06 2022-08-09 Takeda Pharmaceutical Company Limited Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
JP7250687B2 (ja) 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
JP7526096B2 (ja) 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
KR20200100713A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
TW202017918A (zh) 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑吖
KR102697358B1 (ko) 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
CN112074515B (zh) 2017-12-19 2025-01-10 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
EP3728210B1 (en) 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EA202192934A1 (ru) * 2017-12-25 2022-02-09 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
BR112020017835A2 (pt) 2018-03-20 2020-12-29 Eisai R&D Management Co., Ltd. Agente de tratamento de epilepsia
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP3816153B1 (en) 2018-06-29 2023-10-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
ES2948793T3 (es) 2018-09-18 2023-09-19 Bristol Myers Squibb Co Acidos cicloheptílicos como antagonistas de LPA
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
WO2020122092A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
LT3917616T (lt) 2019-01-31 2025-08-11 Takeda Pharmaceutical Company Limited Heterocikliniai junginiai ir jų naudojimas
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP3986552B1 (en) 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
US12466804B2 (en) 2019-06-18 2025-11-11 Bristol-Myers Squibb Company Cyclobutyl carboxylic acids as LPA antagonists
ES3054967T3 (en) 2019-06-18 2026-02-09 Bristol Myers Squibb Co Triazole carboxylic acids as lpa antagonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
CA3163200A1 (en) 2019-11-27 2021-06-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN118946554A (zh) 2022-03-28 2024-11-12 拜耳公司 制备顺式-4-氨基四氢呋喃-2-羧酸酯的方法
US20250250230A1 (en) 2022-04-12 2025-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN119730843A (zh) * 2022-06-21 2025-03-28 阿尔克姆斯有限公司 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
JP2025521507A (ja) * 2022-06-21 2025-07-10 アルカームス インコーポレーテッド 置換縮合二環式化合物および関連する治療方法
JP2025521504A (ja) * 2022-06-21 2025-07-10 アルカームス インコーポレーテッド 置換縮合二環式化合物および関連する治療方法
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CN115433102B (zh) * 2022-10-16 2024-02-27 大连双硼医药化工有限公司 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法
KR20250097917A (ko) 2022-10-31 2025-06-30 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물
WO2024116086A1 (en) 2022-11-30 2024-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2765322A (en) 1953-03-03 1956-10-02 Rohm & Haas Preparation of bis(4-glycidyloxyphenyl)-sulfone
US5315013A (en) 1988-01-07 1994-05-24 E. I. Du Pont De Nemours And Company Substituted pyrazole angiotensin II antagonists
DE69726745T2 (de) 1996-07-31 2004-09-30 Shionogi & Co., Ltd. NEUE p-TERPHENYL VERBINDUNGEN
DE19803396A1 (de) 1998-01-29 1999-08-05 Bayer Ag Substituierte Phenyluracile
CA2332452C (en) 1998-05-20 2009-09-08 Osaka Gas Company Limited Nonaqueous secondary cell and method for controlling the same
CA2337098C (en) * 1998-07-24 2008-08-05 Teijin Limited Anthranilic acid derivatives
WO2001000206A1 (en) 1999-06-30 2001-01-04 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitor compounds
WO2003064404A1 (en) 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
JP2003238538A (ja) 2002-02-12 2003-08-27 Nippon Nohyaku Co Ltd 新規４−置換フェニル−５−ハロピリミジン誘導体及びこれを有効成分とする除草剤
JP2005060385A (ja) 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd ２−フランカルボン酸ヒドラジド化合物からなる医薬
MX2007001678A (es) 2004-08-09 2007-04-12 Glaxo Group Ltd Compuestos que potencian el receptor de glutamato y sus usos en medicina.
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
US20070270471A1 (en) 2004-08-09 2007-11-22 Glaxo Group Limited Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
UA92007C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
WO2007005845A1 (en) 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ａｍｐａ受容体増強剤
US20090221643A1 (en) 2006-02-08 2009-09-03 Kevin Michael Thewlis 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia
GB0602560D0 (en) 2006-02-08 2006-03-22 Glaxo Group Ltd Compounds
KR20090082278A (ko) 2006-12-11 2009-07-29 일라이 릴리 앤드 캄파니 Ａｍｐａ 수용체 강화제
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
CA2682849C (en) 2007-04-03 2012-05-29 Pfizer Inc. Sulfonamides and pharmaceutical compositions thereof
AR069781A1 (es) 2007-12-19 2010-02-17 Glaxo Group Ltd Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
GB0801220D0 (en) * 2008-01-23 2008-02-27 Glaxo Group Ltd Compounds
GB0801265D0 (en) 2008-01-23 2008-02-27 Glaxo Group Ltd Compounds
JPWO2009119088A1 (ja) 2008-03-25 2011-07-21 武田薬品工業株式会社 複素環化合物
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
EP2356099A1 (en) 2008-10-08 2011-08-17 Pfizer Inc. Tetrahydrofuranyl sulfonamides for use as ampa modulators in the treatment of cns disorders
EP2417101B1 (en) * 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
AP3066A (en) 2009-06-26 2014-12-31 Pfizer Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof
EP2456442A1 (en) * 2009-07-23 2012-05-30 Novartis AG 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis
PE20131116A1 (es) * 2010-08-10 2013-10-24 Takeda Pharmaceutical Compuestos heterociclicos potenciadores de ampa

Similar Documents

Publication Publication Date Title
JP2014523851A5 (enExample)
JP2013528204A5 (enExample)
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
DK1700856T3 (en) thiazole
JP2018524390A5 (enExample)
JP6925435B2 (ja) ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法
JP2015500861A5 (enExample)
JP2017502940A5 (enExample)
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
JP2016517406A5 (enExample)
JP2014526435A5 (enExample)
JP2015509110A5 (enExample)
JP2016515560A5 (enExample)
JP2016534134A5 (enExample)
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
JP2014530900A5 (enExample)
JP2014511891A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2014507455A5 (enExample)
JP2016514117A5 (enExample)
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
JP2019510794A5 (enExample)
JP2017509676A5 (enExample)
RU2015141360A (ru) Ингибиторы тирозинкиназы брутона
RU2013125338A (ru) Производные триазола в качестве лигандов рецепторов гамк